期刊文献+

肾移植患者霉酚酸血药浓度人工神经网络预测模型 被引量:3

An Artificial Neural Network Prediction Model for Plasma Concentrations of Mycophenolic Acid in Renal Transplantation Recipients
原文传递
导出
摘要 目的建立人工神经网络模型用于有限采样点估算霉酚酸(MPA)的药动学。方法 64例肾移植受者于术后不同时间服用霉酚酸酯(MMF)前以及服药后0.5、1、1.5、2、3、4、6、8、10、12 h等11个时点采取外周静脉血,采用高效液相色谱法测定血浆MPA浓度,采用遗传算法配合动量法优化网络参数,建立人工神经网络模型。结果以服药前及服用MMF 0.5、2 h后血药浓度数据预测MPA药动学,人工神经网络平均预测误差(MPE)与平均绝对误差(MAE)分别为(0.39±1.24)和(0.90±0.94)μg·mL-1。以MPA预测浓度计算的药动学参数与实际浓度计算的药动学参数无显著差异(P>0.05)。结论人工神经网络可用于有限采样点法预测MPA药动学过程。 ObjectiveTo establish an artificial neural network (ANN) for predicting mycophenolic acid (MPA) pharmacokinetics in renal transplantation recipients by limited sampling strategy. Methods Sixty-four Chinese renal transplantation recipients receiving mycophenolate mofetil (MMF) were investigated. Eleven serum samples were drawn on different days after transplantation. MPA plasma concentration was determined by HPLC and ANN was established after the network parameters were optimized by using momentum method combined with genetic algorithm. Results When using MPA plasma concentrations at 0, 0.5 and 2 h after MMF administration to predict MPA concentration, the mean prediction error and mean absolute prediction error were (0.39±1.24) and (0.90±0.94) μg·mL-1, respectively. There was no significant difference between the pharmacokinetic parameters obtained from the predicted MPA concentrations vs those obtained from the measured MPA concentrations. CONCLUSON ANN can be used to predict MPA pharmacokinetics by limited sampling strategy.
出处 《中国药学杂志》 CAS CSCD 北大核心 2013年第14期1200-1203,共4页 Chinese Pharmaceutical Journal
基金 广东省医院药学研究基金课题(200731)
关键词 霉酚酸 药动学 肾移植 人工神经网络 mycophenolic acid, pharmacokinetics, renal transplantation, artificial neural netword
  • 相关文献

参考文献4

二级参考文献26

共引文献37

同被引文献60

  • 1马雪,李红健,赵婷,王婷婷,冯杰,李佐萍,于鲁海.利用GA-BP神经网络预测新疆癫痫患儿拉莫三嗪血药浓度[J].新疆医学,2022,52(7):847-851. 被引量:3
  • 2刘朝晖,黄榕波,陈庆强,温预关,李明亚.径向基神经网络预测氯氮平血药浓度[J].中国药房,2011,22(14):1273-1275. 被引量:2
  • 3郑春霞,刘志红,秦卫松,曾彩虹,黎磊石.肾小球疾病患者霉酚酸血药浓度监测及其临床意义[J].肾脏病与透析肾移植杂志,2007,16(5):406-413. 被引量:10
  • 4ZAHR N, ARNAUD L, MARQUET P, et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil[J]. Arthritis Rheum, 2010, 62(7): 2047-2054.
  • 5KNIGHT S R, MORRIS P J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice[J]. Transplantation, 2008, 85(12): 1675-1685.
  • 6ABD RAHMAN A N, TETT S E, STAATZ C E. How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?[J]. Clin Pharmacokinet, 2014, 53(3): 227-245.
  • 7MOHAMMADPOUR A H, NAZEMIAN B, ABTAHI B, et al. Estimation of abbreviated mycophenolic acid area under the concentration-time curve during early posttransplant period by limited sampling strategy[J]. Transplant Proc, 2008, 40(10): 3668-3672.
  • 8BLAND J M, ALTMAN D G. Statistical methods for assessing agreement between two methods of clinical measurement[J]. Lancet, 1986,327(8476): 307-310.
  • 9KUYPERS D R, LE MEUR Y, CANTAROVICH M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation[J]. Clin J Am Soc Nephrol, 2010, 5(2): 341-358.
  • 10FILLER G, HANSEN M, LEBLANC C, et al. Pharmacokinetics of mycophenolatemofetil for autoimmune disease in children[J]. Pediatr Nephrol, 2003,18(5): 445-449.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部